Research ArticleSystemic Lupus Erythematosus

Disease Flare of Systemic Lupus Erythematosus in Patients With Endstage Renal Disease on Dialysis

Young-Eun Kim, Su Jin Choi, Doo-Ho Lim, Hyosang Kim, Soo Min Ahn, Ji Seon Oh, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo and Seokchan Hong
The Journal of Rheumatology October 2022, 49 (10) 1131-1137; DOI: https://doi.org/10.3899/jrheum.220101

REFERENCES

  1. 1.↵
    1. Houssiau FA.
    Management of lupus nephritis: an update. J Am Soc Nephrol 2004;15:2694-704.
    OpenUrlFREE Full Text
  2. 2.
    1. Houssiau FA,
    2. Ginzler EM.
    Current treatment of lupus nephritis. Lupus 2008;17:426-30.
    OpenUrlCrossRefPubMed
  3. 3.
    1. Ward MM.
    Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004. J Rheumatol 2009;36:63-7.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Gisca E,
    2. Duarte L,
    3. Farinha F,
    4. Isenberg DA.
    Assessing outcomes in a lupus nephritis cohort over a 40-year period. Rheumatology 2021;60:1814-22.
    OpenUrlPubMed
  5. 5.↵
    1. Coplon NS,
    2. Diskin CJ,
    3. Petersen J,
    4. Swenson RS.
    The long-term clinical course of systemic lupus erythematosus in end-stage renal disease. N Engl J Med 1983;308:186-90.
    OpenUrlCrossRefPubMed
  6. 6.
    1. Lee PT,
    2. Fang HC,
    3. Chen CL,
    4. Chiou YH,
    5. Chou KJ,
    6. Chung HM.
    Poor prognosis of end-stage renal disease in systemic lupus erythematosus: a cohort of Chinese patients. Lupus 2003;12: 827-32.
    OpenUrlCrossRefPubMed
  7. 7.
    1. Pahl MV,
    2. Gollapudi S,
    3. Sepassi L,
    4. Gollapudi P,
    5. Elahimehr R,
    6. Vaziri ND.
    Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant 2010;25:205-12.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Ribeiro FM,
    2. Fabris CL,
    3. Bendet I,
    4. Lugon JR.
    Survival of lupus patients on dialysis: a Brazilian cohort. Rheumatology 2013; 52:494-500.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Okano K,
    2. Yumura W,
    3. Nitta K, et al.
    Analysis of lupus activity in end-stage renal disease treated by hemodialysis. Intern Med 2001;40:598-602.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Barrera-Vargas A,
    2. Quintanar-Martínez M,
    3. Merayo-Chalico J,
    4. Alcocer-Varela J,
    5. Gómez-Martín D.
    Risk factors for systemic lupus erythematosus flares in patients with end-stage renal disease: a case-control study. Rheumatology 2016;55:429-35.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Cucchiari D,
    2. Graziani G,
    3. Ponticelli C.
    The dialysis scenario in patients with systemic lupus erythematosus. Nephrol Dial Transplant 2014;29:1507-13.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Kang SH,
    2. Chung BH,
    3. Choi SR, et al.
    Comparison of clinical outcomes by different renal replacement therapy in patients with end-stage renal disease secondary to lupus nephritis. Korean J Intern Med 2011;26:60-7.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Ribeiro FM,
    2. Leite MA,
    3. Velarde GC,
    4. Fabris CL,
    5. Santos RC,
    6. Lugon JR.
    Activity of systemic lupus erythematosus in end-stage renal disease patients: study in a Brazilian cohort. Am J Nephrol 2005;25:596-603.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Weng CH,
    2. Hsu CW,
    3. Yu CC,
    4. Yen TH,
    5. Yang CW,
    6. Hung CC.
    Peritoneal dialysis and hemodialysis in systemic lupus erythematosus patients: comparison of clinical outcomes. Kidney Blood Press Res 2009;32:451-6.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Nossent HC,
    2. Swaak TJ,
    3. Berden JH.
    Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Dutch Working Party on SLE. Am J Med 1990;89:169-74.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Tan EM,
    2. Cohen AS,
    3. Fries JF, et al.
    The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Weening JJ,
    2. D’Agati VD,
    3. Schwartz MM, et al.
    The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-50.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Li PK,
    2. Szeto CC,
    3. Piraino B, et al.
    ISPD Peritonitis Recommendations: 2016 update on prevention and treatment. Perit Dial Int 2016;36:481-508.
    OpenUrlFREE Full Text
  19. 19.↵
    1. Buttgereit F,
    2. da Silva JA,
    3. Boers M, et al.
    Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002;61:718-22.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Ruperto N,
    2. Hanrahan LM,
    3. Alarcón GS, et al.
    International consensus for a definition of disease flare in lupus. Lupus 2011;20:453-62.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Szeto CC,
    2. Li PK,
    3. Wong TY,
    4. Leung CB,
    5. Lui SF.
    Factors associated with active systemic lupus erythematosus after endstage renal disease. J Rheumatol 1998;25:1520-5.
    OpenUrlPubMed
  22. 22.↵
    1. Mattos P,
    2. Santiago MB.
    Disease activity in systemic lupus erythematosus patients with end-stage renal disease: systematic review of the literature. Clin Rheumatol 2012;31:897-905.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Amore A,
    2. Coppo R.
    Immunological basis of inflammation in dialysis. Nephrol Dial Transplant 2002;17 Suppl 8:16-24.
    OpenUrlPubMed
  24. 24.↵
    1. Altieri P,
    2. Sau G,
    3. Cao R, et al.
    Immunosuppressive treatment in dialysis patients. Nephrol Dial Transplant 2002;17 Suppl 8:2-9.
    OpenUrlPubMed
  25. 25.↵
    1. Jorge A,
    2. Lu N,
    3. Choi H,
    4. Esdaile JM,
    5. Lacaille D,
    6. Avina-Zubieta JA.
    Hydroxychloroquine use and cardiovascular events among patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Care Res 2021;10.1002/acr.24850.
  26. 26.↵
    1. Haubitz M,
    2. Bohnenstengel F,
    3. Brunkhorst R,
    4. Schwab M,
    5. Hofmann U,
    6. Busse D.
    Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 2002;61:1495-501.
    OpenUrlCrossRefPubMed
  27. 27.
    1. MacPhee IA,
    2. Spreafico S,
    3. Bewick M, et al.
    Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. Kidney Int 2000;57:1164-8.
    OpenUrlCrossRefPubMed
  28. 28.
    1. Venkataramanan R,
    2. Ptachcinski RJ,
    3. Burckart GJ,
    4. Yang SL,
    5. Starzl TE,
    6. Van Theil DH.
    The clearance of cyclosporine by hemodialysis. J Clin Pharmacol 1984;24:528-31.
    OpenUrlPubMed
  29. 29.↵
    1. Ptachcinski RJ,
    2. Venkataramanan R,
    3. Rosenthal JT,
    4. Burckart GJ,
    5. Taylor RJ,
    6. Hakala TR.
    Cyclosporine kinetics in renal transplantation. Clin Pharmacol Ther 1985;38:296-300.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Bertsias GK,
    2. Tektonidou M,
    3. Amoura Z, et al.
    Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71:1771-82.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Perl J,
    2. Fuller DS,
    3. Bieber BA, et al.
    Peritoneal dialysis-related infection rates and outcomes: results from the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). Am J Kidney Dis 2020;76:42-53.
    OpenUrlPubMed
  32. 32.↵
    1. Huang JW,
    2. Hung KY,
    3. Yen CJ,
    4. Wu KD,
    5. Tsai TJ.
    Systemic lupus erythematosus and peritoneal dialysis: outcomes and infectious complications. Perit Dial Int 2001;21:143-7.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Shafi ST,
    2. Gupta M.
    Risk of vascular access thrombosis in patients with systemic lupus erythematosus on hemodialysis. J Vasc Access 2007;8:103-8.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section

Keywords

dialysis
ENDSTAGE RENAL DISEASE
immunosuppressant
LUPUS NEPHRITIS
SYSTEMIC LUPUS ERYTHEMATOSUS

Keywords